Status:
COMPLETED
Pharmacokinetics of Insulin Detemir in Healthy Volunteers From Taiwan
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Healthy
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
This trial is conducted in Asia. The aim of this trial is to investigate pharmacokinetics of insulin detemir in healthy Taiwanese subjects.
Eligibility Criteria
Inclusion
- Considered generally healthy upon completion of medical history and physical examination as judged by the investigator
- Body mass index (BMI) between 18 and 27 kg/m\^2, inclusive
- Fasting plasma glucose maximum 6.1 mmol/l
- Non-smoker or smoking maximum 5 cigarettes per day or the equivalent
Exclusion
- Participation in any other clinical trial involving other investigational products within the last 3 months
- Subject with a history of alcohol or drug dependence
- Subject with a first-degree relative with diabetes mellitus
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2005
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01497587
Start Date
August 1 2005
End Date
December 1 2005
Last Update
January 31 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Taipei, Taiwan, 112